BPG is committed to discovery and dissemination of knowledge
Articles in Press
1/29/2026 3:48:21 AM | Browse: 2 | Download: 0
| Category |
Medicine, Research & Experimental |
| Manuscript Type |
Review |
| Article Title |
Gut microbiota-derived metabolite trimethylamine N-oxide in major adverse cardiovascular events: Mechanisms, risk assessment, and therapeutic strategies
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Samuel Jaimez Alvarado, María Fernanda Flores Enciso, Amedeo Amedei and María Magdalena Aguirre García |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Dirección General de Asuntos del Personal Académico-Programa de Apoyo a Proyectos de Investigación e Innovación Tecnológica |
IN219025 |
| Consejo Nacional de Humanidades, Ciencias y Tecnologías |
CBF2023-2024-734 |
|
| Corresponding Author |
Amedeo Amedei, Full Professor, Department of Experimental and Clinical Medicine, University of Florence, Largo Brambilla, 3, Florence 50134, Tuscany, Italy. amedeo.amedei@unifi.it |
| Key Words |
Trimethylamine N-oxide; Major adverse cardiovascular event; Atherosclerosis; Prognosis biomarker; 3,3-dimethyl-1-butanol; Fluoromethylcholine |
| Core Tip |
Trimethylamine N-oxide (TMAO) is increasingly proposed as a prognostic biomarker and therapeutic target in cardiovascular disease, yet its clinical signal is strongly shaped by renal function and cardiometabolic comorbidity. We synthesize evidence linking TMAO to risk stratification, including incremental value beyond GRACE in acute coronary syndrome, highlight mechanistic advances from microbiota-targeted trimethylamine-lyase inhibitors, 3,3-dimethyl-1-butanol/fluoromethylcholine, that improve vascular and cardiac phenotypes in preclinical models, and outline a precision-nutrition framework that tailors TMAO-lowering strategies to individual producer metabotypes. |
| Citation |
Jaimez Alvarado S, Flores Enciso MF, Amedei A, Aguirre García MM. Gut microbiota-derived metabolite trimethylamine N-oxide in major adverse cardiovascular events: Mechanisms, risk assessment, and therapeutic strategies. World J Cardiol 2026; In press |
 |
Received |
|
2025-11-20 05:40 |
 |
Peer-Review Started |
|
2025-11-20 06:25 |
 |
First Decision by Editorial Office Director |
|
2025-12-09 08:40 |
 |
Return for Revision |
|
2025-12-09 08:40 |
 |
Revised |
|
2025-12-22 20:28 |
 |
Publication Fee Transferred |
|
|
 |
Second Decision by Editor |
|
2026-01-29 02:33 |
 |
Second Decision by Editor-in-Chief |
|
|
 |
Final Decision by Editorial Office Director |
|
2026-01-29 03:48 |
 |
Articles in Press |
|
2026-01-29 03:48 |
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
|
| ISSN |
1949-8462 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
© 1993-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345